The editors of the MIT Technology Review highlighted Gu’s work on a novel way to monitor and treat diabetes.
New study in Diabetes Care suggests new delayed-release metformin could help 40 percent of type 2 diabetes patients that currently can’t take metformin.
The finding published in PLoS One suggests that elevated oxidized LDL cholesterol and fructosamine – a measure of glycated proteins in blood sugar – are signposts for the development of severe coronary disease, especially in females.
A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.
TV segment focused diabetes prevention and screening and featured John Buse, MD, PhD, chief, Division of Endocrinology, executive associate dean for clinical research.
The research by Zhen Gu, PhD, assistant professor in the UNC-NCSU joint department of biomedical engineering, aims to improve methods for delivering precise amounts of medications less frequently.
By treating people earlier, doctors could help diabetes patients avoid the most severe, life-threatening complications that stem from prolonged periods of elevated blood glucose.
UNC researchers overturn a controversial study about DPP-4 inhibitors – commonly prescribed diabetes medications.
Participating in the chat will be two diabetes experts and co-authors of a new American Diabetes Association position statement on the care of people with type 1 diabetes.
The Bamberg Diabetes Transitional Care Study will utilize cutting-edge iPad technology to explore the impact and feasibility of different diabetes interventions for patients transitioning from the hospital to home.
John B. Buse, MD, PhD, chief of the division of endocrinology and director of the Diabetes Care Center, has been ranked as one of the world’s foremost experts in type 2 diabetes based on an analysis of publications in the National Library of Medicine’s MEDLINE database.
The newest American Diabetes Association treatment guidelines for the disease are in place at UNC Medical Center.
Collaboration will leverage big data to help providers engage patients to manage diabetes, improve health
The ENDO Trial is currently enrolling adults between the ages of 21 and 65 who have uncontrolled type 2 diabetes and are obese.
Beginning recruitment in June, the project is called the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study. UNC will enroll patients at locations in Durham and Greensboro, N.C.
The Patient-Centered Outcomes Research Institute awards UNC School of Medicine researchers more than $2 million to study glucose monitoring in non-insulin treated patients living with type 2 diabetes.
An investigation into diabetes-related outcomes in a rat model, with senior author William Valdar, PhD, assistant professor of genetics at UNC, and first author Leah Solberg Woods, PhD, from the Medical College of Wisconsin, has made the editor's pick in this month's Physiological Genomics, a journal of the American Physiological Society.
The 2013 Harold Hamm International Prize for Biomedical Research in Diabetes encourages research focused on progress toward a cure.
Daily injections of liraglutide were slightly more effective than weekly injections of exenatide in lowering blood sugar and promoting weight loss. However, patients had fewer negative side effects on exenatide once weekly.
Overall, eleven specialties at UNC Hospitals were recognized as nationally ranked or high performing by U.S. News & World Report in its annual "America's Best Hospitals" issue.